| Not Yet Recruiting | VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML NCT07407140 | Institute of Hematology & Blood Diseases Hospital, China | Phase 3 |
| Recruiting | Quality of Life-Guided Transfusion in Refractory MDS or AML NCT07328191 | Centre Hospitalier Universitaire de Nice | N/A |
| Recruiting | Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients NCT07132684 | Institute of Hematology & Blood Diseases Hospital, China | Phase 3 |
| Recruiting | Observational Study on the Outcome of AML Patients Treated With New Drugs in Real-life (BoxTrial) NCT06513273 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Recruiting | Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML NCT06533761 | Stelexis BioSciences | Phase 1 |
| Not Yet Recruiting | Study of Tretinoin Capsules in Combination With Azacitidine and Venetoclax in Treatment Naïve Participants Wit NCT06841952 | The First Affiliated Hospital of Soochow University | N/A |
| Not Yet Recruiting | Avapritinib Maintenance for AML With KIT Mutations NCT06765915 | Ruijin Hospital | Phase 2 |
| Recruiting | Venetoclax-Decitabine in Untreated Elderly/Unfit AML NCT07117422 | The Second Hospital of Hebei Medical University | N/A |
| Not Yet Recruiting | Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT NCT06765928 | Ruijin Hospital | Phase 2 |
| Recruiting | Revumenib in Combination With 7+3 + Midostaurin in AML NCT06313437 | Richard Stone, MD | Phase 1 |
| Recruiting | Pharmacoscopy-guided Clinical Standard-of-care in r/r AML NCT06138990 | ETH Zurich | Phase 2 |
| Recruiting | OBServatory of Compassionate Use of IVOsidenib in France for Patients With Acute Myeloid Leukemia NCT06377579 | French Innovative Leukemia Organisation | — |
| Recruiting | Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML NCT06420063 | Essen Biotech | Phase 1 / Phase 2 |
| Recruiting | Results From a French Temporary Utilization Authorization of First-line Acute Myeloid Leukemia (AML) Patients NCT06263387 | French Innovative Leukemia Organisation | — |
| Not Yet Recruiting | Kinetics and Impact on Survival of MRD in AML Patients Receiving Azacitidine and Venetoclax NCT06090786 | Gruppo Italiano Malattie EMatologiche dell'Adulto | N/A |
| Not Yet Recruiting | D-index as a Predictor of Complication of Treatment of Patients With Acute Myeloid Leukemia NCT06188182 | Assiut University | — |
| Not Yet Recruiting | Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR NCT06297772 | Ruijin Hospital | Phase 3 |
| Recruiting | MRD-positive AML Clinical Study NCT07131059 | Institute of Hematology & Blood Diseases Hospital, China | N/A |
| Recruiting | Natural Killer(NK) Cell Therapy Targeting CLL1 or CD33 in Acute Myeloid Leukemia NCT06367673 | Zhejiang University | Phase 1 |
| Recruiting | A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly D NCT06014489 | Stichting Hemato-Oncologie voor Volwassenen Nederland | Phase 2 |
| Recruiting | Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilter NCT06022003 | French Innovative Leukemia Organisation | Phase 2 |
| Recruiting | Novel Approaches to Target MECOM/EVI1 in AML NCT05839392 | Gruppo Italiano Malattie EMatologiche dell'Adulto | N/A |
| Recruiting | A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML) NCT05947344 | Zhejiang ACEA Pharmaceutical Co. Ltd. | Phase 1 |
| Recruiting | A Study of Chidamide With AZA in MRD Positive AML After Transplant NCT06066905 | Guangdong Provincial People's Hospital | N/A |
| Recruiting | Assessment of Geriatric Evaluations Impact on New AML Guidance NCT05909501 | Abramson Cancer Center at Penn Medicine | — |
| Active Not Recruiting | A Study of BN104 in the Treatment of Acute Leukemia NCT06052813 | Institut de Recherches Internationales Servier (I.R.I.S.) | Phase 1 / Phase 2 |
| Recruiting | IL-6: A Marker for AML Chemo Sensitivity NCT06486350 | Fujian Medical University Union Hospital | — |
| Recruiting | Natural Killer(NK) Cell Therapy Targeting CLL1 in Acute Myeloid Leukemia NCT06027853 | Zhejiang University | Phase 1 |
| Completed | Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia NCT05987696 | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 |
| Recruiting | A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participa NCT05736965 | Shanghai Tong Ren Hospital | Phase 2 |
| Unknown | Natural Killer(NK) Cell Therapy in r/r AML NCT05665114 | Zhejiang University | Phase 1 |
| Unknown | Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia NCT05665075 | Zhejiang University | Phase 1 |
| Unknown | A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagn NCT05503355 | BioSight Ltd. | Phase 1 / Phase 2 |
| Terminated | Natural Killer(NK) Cell Therapy for Acute Myeloid Leukemia NCT05601466 | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 |
| Active Not Recruiting | Venetoclax + Decitabine vs. "7+3" Induction Chemotherapy in Young AML NCT05177731 | Chen Suning | Phase 3 |
| Unknown | Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS NCT04749355 | BioSight Ltd. | Phase 2 |
| Unknown | A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML) NCT04964518 | Ascentage Pharma Group Inc. | Phase 1 / Phase 2 |
| Recruiting | Precision Therapy Versus Standard Therapy in AML and MDS in Elderly NCT05025098 | University Hospital, Akershus | Phase 2 |
| Terminated | A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05) NCT04755244 | ALX Oncology Inc. | Phase 1 |
| Completed | Pitavastatin in Combination With Venetoclax for Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia NCT04512105 | University of California, Irvine | Phase 1 |
| Terminated | FT538 in Subjects With Advanced Hematologic Malignancies NCT04614636 | Fate Therapeutics | Phase 1 |
| Active Not Recruiting | NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS NCT04623944 | Nkarta, Inc. | Phase 1 |
| Active Not Recruiting | Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS NCT04482894 | University of Virginia | Phase 2 |
| Terminated | Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia NCT04425655 | University of California, San Diego | Phase 2 |
| Terminated | HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt. NCT04496999 | Insel Gruppe AG, University Hospital Bern | Phase 1 |
| Active Not Recruiting | Quality of Life Model for Older Patients With AML NCT04380441 | H. Lee Moffitt Cancer Center and Research Institute | — |
| Withdrawn | Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML a NCT04128020 | Sherif Farag | Phase 1 |
| Terminated | Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib NCT04079738 | H Scott Boswell | Phase 1 / Phase 2 |
| Terminated | A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS NCT03884829 | Cyclacel Pharmaceuticals, Inc. | Phase 1 |
| Withdrawn | EPITHINK: Epigenetic Drug Treatment and Therapeutic Immunotherapy With NKR-2 NCT03612739 | Celyad Oncology SA | Phase 1 |
| Completed | Italian Registry on the Prevalence of IDH1/IDH2 Mutations in Patients With Acute Myeloid Leukemia NCT02986620 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Completed | Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT03194685 | Fujifilm Pharmaceuticals U.S.A., Inc. | Phase 1 |
| Recruiting | Epidemiological Study of a Prospective Cohort of Patients Aged 60 and Over Managed for Acute Myeloid Leukemia NCT06891144 | French Innovative Leukemia Organisation | — |